SymBio Pharmaceuticals
SymBio Pharmaceuticals aims to develop drugs for patients overlooked by the industry, ensuring vital treatments reach those in need.
Launch date
Employees
Market cap
$85.0m
Enterprise valuation
$36m (Public information from Sep 2024)
Share price
JPY252 4582.T
Durham North Carolina (HQ)
Financials
Estimates*
| JPY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 2.8b | 3.0b | 8.3b | 10.0b | 5.6b | 1.7b |
| % growth | - | 5 % | 176 % | 21 % | (44 %) | (70 %) |
| EBITDA | (4.3b) | (5.0b) | 1.1b | 2.0b | (249m) | - |
| % EBITDA margin | (150 %) | (166 %) | 13 % | 20 % | (4 %) | - |
| Profit | (4.4b) | (4.1b) | 2.0b | 1.2b | (2.0b) | - |
| % profit margin | (154 %) | (137 %) | 25 % | 12 % | (35 %) | - |
| EV / revenue | - | - | - | 1.9x | 0.7x | - |
| EV / EBITDA | - | - | - | 9.8x | -15.7x | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Seed | ||
N/A | Series A | ||
| N/A | JPY4.9m | Early VC | |
JPY2.0b | Series B | ||
JPY718m | Late VC | ||
$618m | Late VC | ||
$24.0m | Series E | ||
| N/A | N/A | IPO | |
JPY1.0b | Post IPO Equity | ||
JPY3.0b | Post IPO Debt | ||
| Total Funding | $663m | ||
Related Content
Recent News about SymBio Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.